Ultragenyx posts trial data backing Phase 3 design for Angelman syndrome therapy
seekingalpha
2024-11-10
Shidlovski
Ultragenyx Pharmaceutical (NASDAQ:RARE) announced Saturday that GTX-102, its candidate for the rare neuro-genetic disorder Angelman syndrome, improved patient outcomes across multiple domains in a Phase 1/2 trial, supporting a Phase 3 trial design.
Citing Bayley-4 Cognition Growth Scale Value (GSV), an assessment
免責聲明：投資有風險，本文並非投資建議，以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請，作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考，不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證，投資者應自行研究並在投資前尋求專業建議。
熱議股票
- 1
- 2
- 3
- 4
- 5
- 6
- 7
- 8
- 9
- 10